ITGAX and acquired polycythemia vera: Interestingly, the frequency of CD11c+ B cells was 1.6 times higher in the relapse groups at month 36 when compare to baseline at day 0 (mean, 25 ± 6% at day 0 vs. 40 ± 6% at month 36, n = 5), while in the group of PV patients with no relapse, the frequency of CD11c+ B decreased at month 36 when compare to baseline at day 0 (mean, 22 ± 5% at day 0 vs. 16 ± 4% at month 36, n = 9).